(GLYC) - Earnings & Price History

GLYC: - 11.14, $364.21M, -0.36 (-3.13%)

Sector: Healthcare - Industry: Biotechnology

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. Its GMI-1359, a combined CXCR4 and E-selectin antagonist, being readied for the clinical development. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.Key Statistics

Past GLYC reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-01AMC-0.356.46.336.286.196.67-0.79%1.91%1.11%21.93K
2017-02-28BMO-0.356.116.386.366.086.42-0.31%-3.93%-4.23%17.11K
2017-02-27BMO-0.356.386.366.216.216.45-2.36%2.74%0.31%32.06K
2016-11-04BMO-0.445.795.85.845.7460.69%▲-0.86%-0.17%39.55K
2016-08-04BMO-0.458.498.538.558.428.620.23%-0.70%-0.47%28.61K
2016-05-04BMO-0.476.056.256.255.886.23-3.20%-3.20%46.24K
2016-05-03AMC-0.476.056.256.255.886.23-3.20%-3.20%46.24K
2015-11-12-0.46.86.886.836.566.91-0.73%▲-0.44%-1.16%27.36K
2015-10-30-0.4
2015-10-29-0.46.596.76.736.296.90.45%▲-2.08%-1.64%9.72K
2014-10-30Glycomimetics0.2-0.357.1376.756.757.25-3.57%▲5.63%1.86%10.20K
2014-08-14Glycomimetics0.240.397.867.757.967.698.012.71%-1.26%1.42%15.00K
2014-06-30Glycomimetics-0.28-0.39.188.438.418.089.5-0.24%9.16%8.90%317.20K

Login | Register
Friday Nov 16, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades